Nymox Pharmaceutical CorpOTC Pink - Current Information:NYMXF
- LAST PRICE0.3000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.3050 / 0.3000
- Day Range
- 52 Week Range
- Volume3,833
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NYMXF |
|---|---|---|
| 09:36 ET | 100 | 0.305 |
| 12:32 ET | 100 | 0.27 |
| 02:06 ET | 1000 | 0.3 |
| 02:49 ET | 2500 | 0.3 |
| 03:34 ET | 128 | 0.3 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nymox Pharmaceutical Corp | 28.0M | -5.6x | --- |
Iterum Therapeutics PLC | 27.4M | -0.6x | --- |
Surrozen Inc | 28.7M | -0.4x | --- |
Enlivex Therapeutics Ltd | 26.8M | -0.9x | --- |
BioVie Inc | 26.6M | -0.4x | --- |
Pluri Inc | 28.0M | -1.1x | --- |
Company Information
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.
Contact Information
- Headquarters
- St. Laurent 9900 Cavendish Blvd Suite 306SAINT-LAURENT, QC, Canada H4M 2V2
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Averback
- Chief Financial Officer
- Christopher Riley
- Vice President, General Counsel, Director
- Patrick Doody
- General Counsel, Director
- Randall Lanham
- Independent Director
- Richard Cutler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 93.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-0.05 |
Book Value | $-0.01 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
